Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


First-In-Class Dapaglifozin Headed For FDA Advisory Committee Review

This article was originally published in The Pink Sheet Daily

Executive Summary

In highly safety-conscious climate for diabetes drugs, safety of SGLT-2 inhibitor dapagliflozin is bound to face intense scrutiny.

You may also be interested in...

Avandia REMS Requires Doctors To Tell Patients About Actos’ CV Safety

The Risk Evaluation and Mitigation Strategy for GlaxoSmithKline’s Avandia (rosiglitazone) includes a prominent role for Takeda’s competing thiazolidinedione Actos (pioglitazone).

Actos' Bladder Cancer Signal May Hinge On Dose, Duration Of Use

A five-year interim analysis of a 10-year epidemiological study showed no significant overall increased risk between exposure to Takeda's pioglitazone and bladder cancer, although an increased risk was seen among patients with the highest cumulative dose and the longest duration of exposure.

Dapagliflozin Performance In Phase III Leaves Concerns, Particularly About Urinary Infections

Efficacy for Bristol-Myers Squibb/AstraZeneca's SGLT-2 inhibitor is arguably lackluster, but drug could still find attractive role as an add-on therapy.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts